Cellular Retention of TKI and Apoptosis Commitment not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108: 697–704. 44. White DL, Radich J, Soverini S, Saunders VA, Frede A, et al. (2011) Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomised to high-dose imatinib achieve better responses, and lower failure rates, than those randomized to standard-dose. Haematologica. 45. Davies A, Jordanides NE, Giannoudis A, Lucas CM, Hatziieremia S, et al. (2009) Nilotinib concentration in cell lines and primary CD34(+) chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters. Leukemia 23: 1999–2006. 46. Giannoudis A, Davies A, Lucas CM, Harris RJ, Pirmohamed M, et al. (2008) Effective dasatinib uptake may occur without human organic cation transporter 1 (hOCT1): implications for the treatment of imatinib-resistant chronic myeloid leukemia. Blood 112: 3348–3354. 47. Heidel FH, Mack TS, Razumovskaya E, Blum MC, Lipka DB, et al. (2012) 3,4- Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells. Ann Hematol 91: 331–344. PLoS ONE | www.plosone.org 16 July 2012 | Volume 7 | Issue 7 | e40853